GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pasithea Therapeutics KTTA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.54

-6.31%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pasithea Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Pasithea Therapeutics is based in Miami Beach, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KTTA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $486,559.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Aug 2021
Employees
15
Head office
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Prof. Lawrence SteinmanExecutive Chairman, Co-Founder, since 2020$297,195
  • Dr. Tiago MarquesChief Executive Officer, Director, since 2020$640,059
  • Mr. Daniel SchneidermanChief Financial Officer$430,223
  • Mr. Simon DumesnilIndependent Director$107,195
  • Dr. Emer LeahyIndependent Director$107,195
  • Mr. Alfred NovakIndependent Director$91,463
  • Mr. Patrick GaynesInvestor Relations, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Pasithea Therapeutics Corp. focuses on CNS disorders and RASopathies with four therapeutic programs.
  • The company operates through Therapeutics and Clinics segments in the US and UK markets.
  • PAS-004 is a lead product candidate for RASopathies and oncology indications.

Weaknesses

  • The company has only 15 full-time employees and a small workforce.
  • Pasithea Therapeutics Corp. went public on 13 August 2021 with limited market presence.
  • The firm's pipeline includes only four programs with three in early discovery stages.

Opportunities

  • The US and UK markets offer growth potential for psychiatric and neurological treatments.
  • RASopathies and CNS disorders represent significant unmet medical needs.
  • PAS-004 targets multiple conditions including NF1 and LMNA cardiomyopathy.

Threats

  • Biotechnology companies face high R&D costs and regulatory hurdles.
  • The small team size may limit rapid development and market expansion.
  • Competition in CNS disorder treatments is intense and growing.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.